NEW YORK, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, today announced new results from the first non-invasive evaluation of liver fibrosis in patients from the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH). The data will be presented on November 17 at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in an oral presentation entitled, "Longitudinal changes in FIB-4 and improvement in...
↧